Not for release, publication or distribution, in whole or in part, in, into or from the United States, Canada, Australia or Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction  

1 July 2008

Vernalis completes sale of Apokyn® and US Commercial Operations and Share Subscription

Vernalis plc (LSE: VER) today announces that it has completed the sale of Apokyn® and its US Commercial Operations (the "Sale") to Ipsen. (Euronext: IPN). The subscription by Ipsen for 35,253,134 new ordinary shares of 5 pence each in the capital of Vernalis ("Ordinary Shares") as part of the Sale arrangements (the "Subscription") also completed today. 

As a result of the issue of the 35,253,134 Ordinary Shares pursuant to the Subscription the current issued ordinary share capital of Vernalis is 363,232,786 Ordinary Shares. Vernalis does not hold any shares in treasury. 

The above total voting rights figure of 363,232,786 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Service Authority's Disclosure and Transparency Rules.

Enquiries:

Vernalis plc                                         +44 (0)118 977 3133

Tony Weir, Chief Financial Officer

Brunswick Group                                +44 (0)20 7404 5959

Jon Coles

Justine McIlroy

• News Channel